CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.
What happened
FDA inspected CTK OTC Laboratories (formerly FMK Labs) in Corona, California, from December 16 to 31, 2024. FDA found inadequate investigations of test results that did not meet specifications, including a low-potency bulk base batch that was re-mixed and adjusted and high-viscosity failures that were released and used in finished batches. FDA also found inadequate process and water system validation, with water samples showing bacteria and fungi, and microbiological test methods not shown to be suitable; the firm's January 21, 2025 response was inadequate.
What FDA found
The firm did not thoroughly investigate unexplained discrepancies or batch failures, including low potency and high viscosity results, and did not find root causes or assess other batches.
21 CFR 211.192The firm lacked adequate written production and process control procedures and could not show its mixing processes were validated for uniformity.
21 CFR 211.100(a)The firm did not validate or properly maintain and sanitize its water system, and water samples contained bacteria and fungi that were not identified.
21 CFR 211.100(a)The firm did not show its microbiological test methods were suitable, including growth promotion and negative control testing, for release testing of its OTC drug products.
21 CFR 211.160(b)
What FDA wants
FDA tells the firm to respond in writing within 15 working days with corrective actions, including independent assessments and remediation plans, retrospective impact assessments or retain-sample testing, and a detailed water system remediation plan. FDA also recommends engaging a qualified CGMP consultant to audit the operation and evaluate corrective actions.
Who should pay attention
- brands that contract CTK/FMK to make OTC creams or sunscreens
- distributors and retailers selling CTK-made OTC drug products
- companies relying on CTK's water and microbiological testing for release
This is a summary. Read the original letter on fda.gov.